|Title:||Incomplete hepatitis B immunization, maternal carrier status, and increased risk of liver diseases: a 20-year cohort study of 3.8 million vaccinees||Authors:||Chien, Yin-Chu
|Keywords:||Adolescent; Carcinoma, Hepatocellular; Child; Child, Preschool; Cohort Studies; Female; Hepatitis B Vaccines; Hepatitis B, Chronic; Humans; Incidence; Infant; Infant, Newborn; Liver Failure, Acute; Liver Neoplasms; Male; Mass Vaccination; Pregnancy; Pregnancy Complications, Infectious; Proportional Hazards Models; Registries; Risk Factors; Taiwan; Young Adult||Issue Date:||Jul-2014||Publisher:||WILEY-BLACKWELL||Source:||Hepatology (Baltimore, Md.)||Abstract:||
Hepatitis B immunization has been documented to prevent fulminant hepatic failure (FHF) and hepatocellular carcinoma (HCC) by historical comparison studies in Taiwan. This study aimed to assess long-term risks and predictors of various liver diseases associated with incomplete immunization in 3.8 million vaccinees. Profiles of the National Hepatitis B Immunization Registry, National Cancer Registry, and National Death Certification Registry were linked to ascertain newly diagnosed cases of HCC and deaths from FHF and chronic liver diseases (CLDs) from infancy to early adulthood of 3,836,988 newborn vaccinees. Cox's proportional hazards models were used to estimate hazard ratios (HRs) for various risk predictors. There were 49 newly developed cases of HCC, 73 deaths from FHF, and 74 deaths from CLDs during the follow-up of 41,854,715 person-years. There were striking differences between unvaccinated and vaccinated newborns after the launch of a national immunization program for HCC incidence (0.293 vs. 0.117 per 100,000 person-years), FHF mortality (0.733 vs. 0.174 per 100,000 person-years), and CLD mortality (2.206 vs. 0.177 per 100,000 person-years). Among vaccinees, incomplete immunization was the most important risk predictor of HCC, FHF, and CLDs, showing an HR (95% confidence interval, P value) of 2.52 (1.25-5.05; P = 0.0094), 4.97 (3.05-8.11; P < 0.0001), and 6.27 (3.62-10.84; P < 0.0001), respectively, after adjustment for maternal hepatitis B serostatus.
|Appears in Collections:||流行病學與預防醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.